Pharsight

Drugs that contain Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate

1. Complera patents expiration

COMPLERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5814639 GILEAD SCIENCES INC Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Sep, 2015

(8 years ago)

US5814639

(Pediatric)

GILEAD SCIENCES INC Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Mar, 2016

(8 years ago)

US5914331 GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(6 years ago)

US5922695 GILEAD SCIENCES INC Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jul, 2017

(6 years ago)

US6043230 GILEAD SCIENCES INC Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5935946 GILEAD SCIENCES INC Nucleotide analog composition and synthesis method
Jul, 2017

(6 years ago)

US5977089 GILEAD SCIENCES INC Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5914331

(Pediatric)

GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jan, 2018

(6 years ago)

US5922695

(Pediatric)

GILEAD SCIENCES INC Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jan, 2018

(6 years ago)

US5977089

(Pediatric)

GILEAD SCIENCES INC Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US6043230

(Pediatric)

GILEAD SCIENCES INC Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US5935946

(Pediatric)

GILEAD SCIENCES INC Nucleotide analog composition and synthesis method
Jan, 2018

(6 years ago)

US7067522 GILEAD SCIENCES INC 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
Dec, 2019

(4 years ago)

US6642245 GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Nov, 2020

(3 years ago)

US6838464 GILEAD SCIENCES INC 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
Feb, 2021

(3 years ago)

US6703396 GILEAD SCIENCES INC Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Mar, 2021

(3 years ago)

US6642245

(Pediatric)

GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
May, 2021

(3 years ago)

US6703396

(Pediatric)

GILEAD SCIENCES INC Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Sep, 2021

(2 years ago)

US8101629 GILEAD SCIENCES INC Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(1 year, 9 months ago)

US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 1 month ago)

US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(4 months ago)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(4 months ago)

US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(4 months ago)

US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(4 months ago)

US8716264

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jul, 2024

(a month from now)

US8841310 GILEAD SCIENCES INC Combinations of a pyrimidine containing NNRTI with RT inhibitors
Dec, 2025

(1 year, 6 months from now)

US10857102 GILEAD SCIENCES INC Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Jan, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 13, 2016
New Chemical Entity Exclusivity(NCE) May 20, 2016

NCE-1 date: 21 May, 2015

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents